BACKGROUND: Obesity is a major public health issue. This review updates the evidence on the effectiveness of behavioural and pharmacologic treatments for overweight and obesity in adults. METHODS: We updated the search conducted in a previous review. Randomized trials of primary-care-relevant behavioural (diet, exercise and lifestyle) and pharmacologic (orlistat and metformin) with or without behavioural treatments in overweight and obese adults were included if 12-month, postbaseline data were provided for weight outcomes. Studies reporting harms were included regardless of design. Data were extracted and pooled wherever possible for 5 weight outcomes, 6 secondary health outcomes and 4 adverse events categories. RESULTS: We identified 68 studies, most consisted of short-term (≤ 12 mo) treatments using diet (n = 8), exercise (n = 4), diet and exercise (n = 10), lifestyle (n = 19), orlistat (n = 25) or metformin (n = 4). Compared with the control groups, intervention participants had a greater weight loss of -3.02 kg (95% confidence interval [CI] -3.52 to -2.52), a greater reduction in waist circumference of -2.78 cm (95% CI -3.34 to -2.22) and a greater reduction in body mass index of -1.11 kg/m(2) (95% CI -1.39 to -0.84). The relative risk for loss of ≥ 5% body weight was 1.77 (95% CI 1.58-1.99, [number needed to treat 5, 95% CI 4-7]), and the relative risk for loss of ≥ 10% body weight was 1.91 (95% CI 1.69-2.16, [number needed to treat 9, 95% CI 7-12]). Incidence of type 2 diabetes was lower among pre-diabetic intervention participants (relative risk 0.62 [95% CI 0.50-0.77], number needed to treat 17 [95% CI 13-29]). With prevalence rates for type 2 diabetes on the rise, weight loss coupled with a reduction in the incidence of type 2 diabetes could potentially have a significant benefit on population health and a possible reduction in need for drug treatments for glycemic control. INTERPRETATION: There is moderate quality evidence that behavioural and pharmacologic plus behvioural, treatments for overweight and obesity in adults lead to clinically important reductions in weight and incidence of type 2 diabetes in pre-diabetic populations. REGISTRATION: PROSPERO no. CRD42012002753.
BACKGROUND:Obesity is a major public health issue. This review updates the evidence on the effectiveness of behavioural and pharmacologic treatments for overweight and obesity in adults. METHODS: We updated the search conducted in a previous review. Randomized trials of primary-care-relevant behavioural (diet, exercise and lifestyle) and pharmacologic (orlistat and metformin) with or without behavioural treatments in overweight and obese adults were included if 12-month, postbaseline data were provided for weight outcomes. Studies reporting harms were included regardless of design. Data were extracted and pooled wherever possible for 5 weight outcomes, 6 secondary health outcomes and 4 adverse events categories. RESULTS: We identified 68 studies, most consisted of short-term (≤ 12 mo) treatments using diet (n = 8), exercise (n = 4), diet and exercise (n = 10), lifestyle (n = 19), orlistat (n = 25) or metformin (n = 4). Compared with the control groups, intervention participants had a greater weight loss of -3.02 kg (95% confidence interval [CI] -3.52 to -2.52), a greater reduction in waist circumference of -2.78 cm (95% CI -3.34 to -2.22) and a greater reduction in body mass index of -1.11 kg/m(2) (95% CI -1.39 to -0.84). The relative risk for loss of ≥ 5% body weight was 1.77 (95% CI 1.58-1.99, [number needed to treat 5, 95% CI 4-7]), and the relative risk for loss of ≥ 10% body weight was 1.91 (95% CI 1.69-2.16, [number needed to treat 9, 95% CI 7-12]). Incidence of type 2 diabetes was lower among pre-diabetic intervention participants (relative risk 0.62 [95% CI 0.50-0.77], number needed to treat 17 [95% CI 13-29]). With prevalence rates for type 2 diabetes on the rise, weight loss coupled with a reduction in the incidence of type 2 diabetes could potentially have a significant benefit on population health and a possible reduction in need for drug treatments for glycemic control. INTERPRETATION: There is moderate quality evidence that behavioural and pharmacologic plus behvioural, treatments for overweight and obesity in adults lead to clinically important reductions in weight and incidence of type 2 diabetes in pre-diabetic populations. REGISTRATION: PROSPERO no. CRD42012002753.
Authors: Karen E Foster-Schubert; Catherine M Alfano; Catherine R Duggan; Liren Xiao; Kristin L Campbell; Angela Kong; Carolyn E Bain; Ching-Yun Wang; George L Blackburn; Anne McTiernan Journal: Obesity (Silver Spring) Date: 2011-04-14 Impact factor: 5.002
Authors: Robert Ross; Miu Lam; Steven N Blair; Timothy S Church; Marshall Godwin; Stephen B Hotz; Ana Johnson; Peter T Katzmarzyk; Lucie Lévesque; Susan MacDonald Journal: Arch Intern Med Date: 2012-02-27
Authors: Ira S Ockene; Trinidad L Tellez; Milagros C Rosal; George W Reed; John Mordes; Philip A Merriam; Barbara C Olendzki; Garry Handelman; Robert Nicolosi; Yunsheng Ma Journal: Am J Public Health Date: 2011-12-15 Impact factor: 9.308
Authors: Punam Parikh; Ellen P Simon; Kezhen Fei; Helen Looker; Crispin Goytia; Carol R Horowitz Journal: Am J Public Health Date: 2010-02-10 Impact factor: 9.308
Authors: Jun Ma; Veronica Yank; Lan Xiao; Philip W Lavori; Sandra R Wilson; Lisa G Rosas; Randall S Stafford Journal: JAMA Intern Med Date: 2013-01-28 Impact factor: 21.873
Authors: M H Davidson; J Hauptman; M DiGirolamo; J P Foreyt; C H Halsted; D Heber; D C Heimburger; C P Lucas; D C Robbins; J Chung; S B Heymsfield Journal: JAMA Date: 1999-01-20 Impact factor: 56.272
Authors: E L Thomas; A Makwana; R Newbould; A W Rao; G Gambarota; G Frost; B Delafont; R G Mishra; P M Matthews; E S Berk; S M Schwartz; J D Bell; J D Beaver Journal: Eur J Clin Nutr Date: 2011-06-22 Impact factor: 4.016
Authors: Linda Penn; Martin White; John Oldroyd; Mark Walker; K George M M Alberti; John C Mathers Journal: BMC Public Health Date: 2009-09-16 Impact factor: 3.295
Authors: Kiran Nanchahal; Tom Power; Elizabeth Holdsworth; Michelle Hession; Annik Sorhaindo; Ulla Griffiths; Joy Townsend; Nicki Thorogood; David Haslam; Anthony Kessel; Shah Ebrahim; Mike Kenward; Andrew Haines Journal: BMJ Open Date: 2012-05-04 Impact factor: 2.692
Authors: Leslea Peirson; Donna Fitzpatrick-Lewis; Donna Ciliska; Muhammad Usman Ali; Parminder Raina; Diana Sherifali Journal: CMAJ Open Date: 2015-01-13
Authors: Paula Brauer; Sarah Connor Gorber; Elizabeth Shaw; Harminder Singh; Neil Bell; Amanda R E Shane; Alejandra Jaramillo; Marcello Tonelli Journal: CMAJ Date: 2015-01-26 Impact factor: 8.262
Authors: Jun Ma; Lisa Goldman Rosas; Nan Lv; Lan Xiao; Mark B Snowden; Elizabeth M Venditti; Megan A Lewis; Jeremy D Goldhaber-Fiebert; Philip W Lavori Journal: JAMA Date: 2019-03-05 Impact factor: 56.272